BioSpace News Archive

MedSelect leverages Prime’s novel medical drug management strategy to drive appropriate use of medical benefit drugs, cost effectiveness and better health outcomes

Genome & Company (KONEX: 314130), a global pioneer company of microbiome therapeutics, initiated clinical trials of GEN-001, an anti-cancer microbiome therapeutic (NCT04601402).

- Influenza A (IVA) animal model confirmed 75% clinical symptom improvement compared to the control group - Broad antiviral efficacy results against SARS-CoV-2 and IVA were presented at the ISIRV-AVG conference

Meat-Tech 3D Ltd. (TASE: MEAT), today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to the potential U.S. initial public offering of American Depositary Shares

Marks largest study of its kind on COVID-19 patients treated with extracorporeal blood purification (EBP) using Oxiris Study investigators assessed serum IL-6 levels, indicators of organ dysfunction and intensive care unit (ICU) mortality rate in patients undergoing EBP with Oxiris Findings provide clinicians with new insights on EBP initiation in COVID-19 patients

Moleculin Biotech, Inc. announced that members of management will participate in a panel at ROTH Capital’s healthcare event titled, “COVID-19 Therapeutics in Development,” taking place on Wednesday, October 28th, 2020.

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its third quarter 2020 financial and operating results on Tuesday, November 3, 2020 before the market opens

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020.

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection

Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.